The patentability of natural phages as therapeutics in the United States
Microbes & Immunity · 2024
DOI: 10.36922/mi.4758 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbes & Immunity, 2024. Verfasst von Qimao Yang und 4 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
The resurgence of phage therapy as a potent countermeasure against antimicrobial resistance has been accompanied by significant challenges in patent protection. This perspective paper examines the patentability of natural phages as therapeutics, focusing on the United States and extending to the European Union and Australia – jurisdictions at the forefront of this biotechnological innovation. We dissect the legal frameworks and identify the patent claims that have successfully navigated the complex intellectual property landscape. Our analysis reveals a dichotomy between the natural origin of therapeutic phages and the inventive steps required for patent eligibility. Despite hurdles, we highlight strategic innovations and specific patent claims that have been granted, suggesting a path forward for the commercialization and protection of phage therapy. We conclude with a call for a more adaptive legal framework to foster innovation and recognize the transformative potential of phage therapy in modern medicine.
Zitieren
APA
Yang, Q., Zeng, S., Zhu, B., Zhu, T., & Wu, N. (2024). The patentability of natural phages as therapeutics in the United States. Microbes & Immunity. https://doi.org/10.36922/mi.4758
Vancouver
Yang Q, Zeng S, Zhu B, Zhu T, Wu N. The patentability of natural phages as therapeutics in the United States. Microbes & Immunity. 2024. doi:10.36922/mi.4758
BibTeX
@article{Yang2024,
author = {Yang, Qimao and Zeng, Shiyi and Zhu, Biao and Zhu, Tongyu and Wu, Nannan},
title = {The patentability of natural phages as therapeutics in the United States},
journal = {Microbes & Immunity},
year = {2024},
doi = {10.36922/mi.4758}
}
EUVIMED